← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #941 OF 1,000 MOST-CITED

Production controls not adequate

FDA cited this observation 15 times across 15 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices15
BY FISCAL YEAR
FY202615

How FDA worded it — real examples

Production controls do not include documentation of procedures and methods for the control of production and implementation of monitoring and measurement of process parameters and product characteristics.

Sciteck Diagnostics · Fletcher, North Carolina · Devices · 2026-06-03

Production controls do not include documentation of procedures and methods for the control of production.

MANSBACH HEALTH TOOLS LLC · Potomac, Maryland · Devices · 2026-06-02

Production controls do not include documentation of procedures and methods for the control of production.

Depuy International Ltd. · Leeds · Devices · 2026-05-29

Production controls do not include qualification of infrastructure.

Domico Med-Device Llc · Fenton, Michigan · Devices · 2026-05-12

Production controls do not include documentation of procedures and methods for the control of production, implementation of monitoring and measurement of process parameters and product characteristics and implementation of defined operations for labeling and packaging.

Marlen Manufacturing & Development Co. · Bedford, Ohio · Devices · 2026-05-06

Production controls do not include documentation of procedures and methods for the control of production.

Triangle Machine, Inc. · South Bend, Indiana · Devices · 2026-04-15

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Medical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →